Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20166817 | 1.00 | APLNR (0.51) | APLNRGBA1 | |
| SCHEMBL18245652 | 1.00 | APLNR (0.51) | APLNRGBA1 | |
| SCHEMBL31324432 | 0.84 | APLNR (0.35) | APLNR | |
| SCHEMBL18245727 | 0.84 | APLNR (0.43) | APLNR | |
| SCHEMBL18246161 | 0.84 | APLNR (0.43) | APLNR | |
| SCHEMBL18247096 | 0.84 | APLNR (0.43) | APLNR | |
| SCHEMBL18245771 | 0.82 | APLNR (0.49) | APLNRGBA1 | |
| SCHEMBL20190471 | 0.81 | APLNR (0.40) | APLNRGBA1 | |
| SCHEMBL19574019 | 0.81 | LMNA (0.43) | APLNR | |
| SCHEMBL18245749 | 0.80 | APLNR (0.46) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20210246118-A1 | SUBSTITUTED PYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2021-08-12 | — | — | US | disclosed |
| EP-3300500-B9 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3300500-B1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246118-A1 | SUBSTITUTED PYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR | APLNR, AGTR1, AGTR2 | APLNR 1/4885GBA1 4661/4885 |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | APLNR, AGTR1, AGTR2 | APLNR 1/4885GBA1 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.